In partnership with
The Bottom Line Upfront 💡
$GDRX ( ▼ 2.87% ) GoodRx still throws off roughly $146M of free cash on a $1.2B market cap, which is why the stock nearly doubled off its lows. The problem is that revenue has now fallen for three straight quarters. At $3.30-$3.60 the discount that made this interesting has closed, and nothing underneath it has improved.
Since We Last Called It 🔁
Last look | The call | Price then | Price now | Since then |
|---|---|---|---|---|
Significantly undervalued | $2.43 | $3.30-$3.60 | +47% (S&P 500 +3%) |
The call worked, and it beat the index by more than 40 points in four months. Be clear about why: nothing in the business got better. First-half revenue fell 2.9% and operating income fell with it. What changed was the multiple, not the company. A re-rating off a depressed base is a one-time gift, and it does not repeat.
Sponsorship
Protect your identity now with Coveron comprehensive coverage
Identity theft is the fastest-growing crime in America. Criminals don't wait to steal everything, they test stolen identities with small charges before launching major fraud. By the time you notice, they've opened credit cards, taken out loans, or claimed tax refunds in your name.
Coveron watches your credit 24/7, monitors the dark web, and alerts you immediately when suspicious activity is detected. We watch, we warn, we help recover:
Up to $1M to cover identity theft recovery costs.
Up to $10K for losses from online scams.
Up to $50K to cover eligible costs, including payments made in response to the threats.
And with dedicated case managers to handle the legal and financial mess.
One scam can cost you everything - protect yourself now. The first 100 users get 20% off with code beehiivenewsletter.
30-day money-back guarantee. Terms and conditions apply.
Strata Layers Chart
Layer 1: The Business Model 🏛️
GoodRx is a coupon company wearing a technology company's clothes, and that is not an insult. American prescription pricing is genuinely broken: the same generic drug can cost $12 at one pharmacy and $80 at another two blocks away, because pharmacy benefit managers negotiate different rates with different chains. GoodRx aggregates those negotiated rates, shows you the cheapest one, and hands you a code to present at the counter.
How the money actually moves. GoodRx sits between the PBM and the pharmacy. When you use a code, the PBM collects a small administrative fee from the pharmacy and shares part of it with GoodRx. You pay nothing. The pharmacy gets a customer who might otherwise have walked away from the prescription entirely. That is the flywheel, and it explains the margins: this is a referral business with essentially no cost of goods.
Three revenue lines:
Prescription transactions (roughly 73% of revenue): the core code business
Pharma manufacturer solutions: drugmakers paying to promote brand medications to people already shopping for that condition
Subscriptions (GoodRx Gold, about 11%): a monthly plan with deeper discounts
The company runs on 697 employees. Capital spending was $3.5M last year against $85M of depreciation and amortisation, almost all of it amortising old acquisitions. It is about as asset-light as a business gets.
Key Takeaway: GoodRx monetises the dysfunction in American drug pricing, which means its business is only as durable as that dysfunction.
Layer 2: Category Position 🏆
GoodRx is the default brand in prescription discounts, with the app downloads and pharmacy counter recognition to prove it. That is worth something. It is not worth as much as it was.
The competitive pressure is coming from three directions at once. Amazon Pharmacy and Cost Plus Drugs sell generics direct at transparent prices, which removes the need for a coupon entirely. Retail pharmacies are consolidating and closing stores, which shrinks the counter network and strengthens the negotiating hand of whoever is left. And manufacturers are experimenting with direct-to-patient pricing, most visibly on the weight loss drugs, which routes around the discount layer altogether.
None of these has killed GoodRx. All of them explain why revenue is flat to down while the American prescription market keeps growing.
Key Takeaway: GoodRx owns the category and the category is being slowly disintermediated by people selling drugs cheaply without a middleman.
Layer 3: Show Me The Money! 📈
The top line is going backwards. Q1 2026 revenue was $194M against $203M a year earlier, down 4.4% ↘️. Q2 2026 was $200M against $203M, down 1.3% ↘️. First half revenue of $394M compares to $406M, a 2.9% decline ↘️. Full year 2025 revenue was $797M, essentially flat on 2024.
Profitability went with it. Q2 operating income was $24M against $28M a year earlier. Net income was $8.5M against $12.8M. Trailing twelve month net income is $16M, which on a $1.2B market cap is a P/E in the seventies. That number is not the right way to look at this company, but it is worth seeing.
Cash is the right way to look at it. Operating cash flow was $168M in 2025 against $3.5M of capital spending. Free cash flow of roughly $146M on the trailing twelve months is a yield near 12%. The gap between $16M of accounting profit and $146M of cash is mostly $85M of non-cash amortisation on acquired intangibles.
One number deserves a flag. Stock-based compensation was $77M in 2025, close to 10% of revenue. Free cash flow does not subtract it, but shareholders pay it. Management has been offsetting the dilution with buybacks, $207M in 2025 and $159M in 2024, taking diluted shares from 379M to 348M.
Net debt is around $243M against $262M of cash on hand. Sales and marketing runs about 41% of revenue, which is what it costs to keep a coupon brand top of mind.
Key Takeaway: A declining business that converts 19 cents of every revenue dollar into free cash is a genuinely awkward thing to value.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Fairly Valued 🤔
Scenario | Fair Value | vs Current Price ($3.30-$3.60) |
|---|---|---|
Conservative | $2.40 | -31% |
Base Case | $3.75 | +8% |
Optimistic | $5.60 | +61% |
Key assumptions:
Conservative assumes free cash flow slips to $130M and keeps eroding about 1% a year, discounted at 11% to reflect a levered small cap with a shrinking top line.
Base case holds free cash flow at $145M with 1% growth at a 10.5% discount rate. This is the current run rate, extended.
Optimistic needs free cash flow to reach $160M and grow 2.5%, which requires revenue to actually turn.
All three subtract $243M of net debt across roughly 348M diluted shares.
One-line take: Four months ago the market was pricing the conservative case and we said so. It is now pricing the base case, which is a fair price rather than a bargain.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
Prescription transaction revenue stabilises and the pharma manufacturer business grows into a second real leg
Buybacks keep retiring 8% of the share count a year, so per-share cash flow rises even if total cash flow does not
American drug pricing stays opaque enough that a price comparison layer remains genuinely useful
Bear Case 🐻
Direct-to-patient pricing from manufacturers and transparent generic sellers keeps eating the reason GoodRx exists
Revenue declines accelerate past 5%, at which point the free cash flow yield is a melting ice cube rather than a bargain
Stock compensation near $77M a year quietly transfers value from shareholders to employees while free cash flow looks untouched
The Bottom Line: GoodRx generates real cash from a real brand in a market that is structurally moving against it. We were right that $2.43 was too low. We are not going to pretend that makes today's price too low as well. This is now a fair price for a business that has to prove it can stop shrinking.
Layer 6: What to Watch 👀
Quarterly revenue growth turning positive. Three consecutive declining quarters. One flat quarter changes the whole thesis, and nothing else matters as much.
Monthly active consumers. The leading indicator ahead of revenue. Continued erosion means the transaction line keeps sliding.
Pharma manufacturer solutions revenue. The one line with genuine growth potential. Watch whether it is scaling or just cycling with drug launches.
Buyback pace against stock compensation. If repurchases fall below roughly $77M a year, net dilution turns positive and the per-share story stops working.
Free cash flow below $120M. The entire valuation rests on the cash yield. Below that level, the conservative case becomes the base case.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.